NCT05392179View on ClinicalTrials.gov

A Study in Subjects With Retinitis Pigmentosa

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

July 14, 2022

Primary Completion Date

June 23, 2023

Study Completion Date

June 23, 2023

Conditions
Retinitis Pigmentosa
Interventions
DRUG

ADX-2191

Monthly intravitreal injections of ADX-2191 (400 µg in 0.05 mL) for a total of three injections. Evaluation through week 16.

DRUG

ADX-2191

Monthly intravitreal injections of ADX-2191 (400 µg in 0.05 mL) for a total of six injections. Evaluation through week 16.

Trial Locations (1)

27710

Duke Eye Center, Durham

Sponsors
All Listed Sponsors
lead

Aldeyra Therapeutics, Inc.

INDUSTRY